The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces...

Clinical Cancer Research 2015 / 06 Vol. 21; Iss. 12

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models

Schuller, A. G., Barry, E. R., Jones, R. D. O., Henry, R. E., Frigault, M. M., Beran, G., Linsenmayer, D., Hattersley, M., Smith, A., Wilson, J., Cairo, S., Deas, O., Nicolle, D., Adam, A., Zinda, M.,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
21
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-14-2685
Date:
June, 2015
File:
PDF, 5.83 MB
english, 2015
Conversion to is in progress
Conversion to is failed